Article
Discovering and targeting dynamic drugging pockets of the oncogene KRAS-G12D
2022-07-02
Abstract excerpt
Activated KRAS-G12D mutations are the one of most frequent oncogenic drivers in human cancers. Unfortunately, no therapeutic agent directly targeting KRAS-G12D has been clinically approved yet, with such mutated species remaining undrugged. Notably, cofactor Mg 2+ is closely related to the function of small GTPases, but no investigation has been done yet on Mg 2+ when associated with KRAS. Herein, through micros...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 79a53ee9-8432-5075-b81b-a44aa6a8b8df
- DOI
- 10.1101/2022.07.01.498403
